Condition: Dengue · Sponsor: Butantan Institute
This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue vaccine (Dengue 1,2,3,4 (attenuated)) in participants aged 60 -79 years (elderly) compared to participants aged 40 to 59 years (adults), with or without previous dengue and healthy based on clinical examination.
This description comes directly from the study's public registry record.
Fabiano Ramos, MD, PhD · +55(51) 3320-5610 · framos@pucrs.br
Always discuss trial participation with your own doctor first.
| CWB 02 - Centro Médico São Francisco | Curitiba, Paraná, Brazil | Recruiting |
| PET 01 - Hospital Escola da Universidade de Pelotas - HEUFPEL | Pelotas, Rio Grande do Sul, Brazil | Recruiting |
| POA 05 - Núcleo de Pesquisa do Rio Grande do Sul | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| POA 02 - Associação Hospitalar Moinhos de Vento | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| POA 01 - Centro de Pesquisa: Hospital São Lucas - PUCRS | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06891950